Social Determinants of Health in Hepatobiliary Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To characterize the social determinants of health - and specifically travel-limiting access to cancer care but also other issues, such as trouble in finding childcare, joblessness, and limited education - among SEA Americans with hepatobiliary cancers, exposure risk including aflatoxin and viral hepatitis among other exposures.
OUTLINE: This is an observational study.
Patients complete a questionnaire, undergo blood, urine, and buccal swab sample collection and have their medical records reviewed on study. Patients also undergo collection of clinically archived tissue samples on study.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Principal Investigator:
- Nguyen H. Tran, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients 18+ year of age with hepatobiliary cancers
Exclusion Criteria:
- Patients under 18 years of age
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observational
Patients complete a questionnaire, undergo blood, urine, and buccal swab sample collection and have their medical records reviewed on study.
Patients also undergo collection of clinically archived tissue samples on study.
|
Non-interventional study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients reporting transportation barriers that affect medical care
Time Frame: Baseline; up to 2 years
|
Estimated using Social Determinants of Health Screening Tool designed by the American Academy of Family Medicine, by the proportion of patients who respond "yes" to the question, "Do you put off or neglect going to the doctor because of distance or transportation?".
|
Baseline; up to 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nguyen H. Tran, M.D., Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 22-012368 (Other Identifier: Mayo Clinic in Rochester)
- NCI-2023-05784 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- K23MD017217 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Hepatobiliary Neoplasm
-
NCT07124546RecruitingMalignant Hepatobiliary Neoplasm
-
NCT03857958UnknownMalignant Hepatobiliary Neoplasm
-
NCT03195075UnknownMalignant Hepatobiliary Neoplasm
-
NCT02265341CompletedMalignant Hepatobiliary Neoplasm
-
NCT06049836Completed
-
NCT04959630Completed
-
NCT04060472Not yet recruitingAdvanced Hepatobiliary and Malignant Tumors
-
NCT02583269CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant Neoplasm
-
NCT06915727RecruitingMalignant Abdominal Neoplasm | Malignant Pelvic Neoplasm | Childhood Malignant Solid Neoplasm | Childhood Malignant Thoracic Neoplasm | Malignant Neck Neoplasm | Metastatic Childhood Malignant Solid Neoplasm
-
NCT02070549CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm
Clinical Trials on Non-Interventional Study
-
NCT07215065CompletedHeavy Metal Exposure From Vaping
-
NCT07613593Not yet recruitingChronic Kidney Disease
-
NCT07325006RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07227038RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma
-
NCT07212491Enrolling by invitationBarrett Esophagus | Esophageal Adenocarcinoma
-
NCT07456436RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07439471RecruitingCigarette Smoking-Related Carcinoma
-
NCT07412002Not yet recruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid Neoplasm
-
NCT07341503RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma
-
NCT07306338RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm